Augmentation of autologous T cell reactivity with acute myeloid leukemia (AML) blasts by Toll-like receptor (TLR) agonists

Cancer Immunology, Immunotherapy

Volumn 64, Issue 6, 2015, Pages 737-744

  Zhong, RuiKun ^a   Li, Hongying ^a   Messer, Karen ^a   Lane, Thomas A ^a   Zhou, Jiehua ^a   Ball, Edward D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Acute myeloid leukemia; Cytotoxic T lymphocytes; Dendritic cells; Lipopolysaccharide; Resiquimod; Toll like receptor

Indexed keywords

B7 ANTIGEN; CD40 ANTIGEN; CD83 ANTIGEN; CD86 ANTIGEN; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 4; LIPOPOLYSACCHARIDE; RESIQUIMOD; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT; IMIDAZOLE DERIVATIVE; TOLL LIKE RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ANTIGEN PRESENTATION; ARTICLE; BONE MARROW DERIVED MONONUCLEAR CELL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CELL LINE; CONTROLLED STUDY; CYTOKINE RELEASE; HUMAN; HUMAN CELL; IMMUNOREACTIVITY; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; T CELL CULTURE; AGONISTS; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFECTS; IMMUNOLOGY; LEUKEMIA, MYELOID, ACUTE; TUMOR CELL CULTURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DENDRITIC CELLS; HUMANS; IMIDAZOLES; INTERFERON-GAMMA; LEUKEMIA, MYELOID, ACUTE; LIPOPOLYSACCHARIDES; T-LYMPHOCYTES, CYTOTOXIC; TOLL-LIKE RECEPTORS; TUMOR CELLS, CULTURED;

EID: 84930416854     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1680-x     Document Type: Article

References (39)

1. Akira S, Uematsu S, Takeuchi O (2006) Pathogen recognition and innate immunity. Cell 124:783–801
2. Barton GM, Kagan JC (2009) A cell biological view of Toll-like receptor function: regulation through compartmentalization. Nat Rev Immunol 9:535–542
3. Medzhitov R, Preston-Hurlburt P, Janeway CA Jr (1997) A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 388:394–397
4. Qureshi ST, Lariviere L, Leveque G (1999) Endotoxin-tolerant mice have mutations in Toll-like receptor 4 (TLR4). J Exp Med 189(4):615–625
5. Hoshino K, Takeuchi O, Kawai T (1999) Cutting edge: Toll-like receptor 4 (TLR4)-deficient mice are hyporesponsive to lipopolysaccharide: evidence for TLR4 as the LPS gene product. J Immunol 162(7):3749–3752
6. Grote K, Schütt H, Schieffer B (2011) Toll-like receptors in angiogenesis. Sci World J 11:981–991
7. Alexopoulou L, Holt AC, Medzhitov R, Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413:732–738
8. Hornung V, Rothenfusser S, Britsch S, Krug A, Jahrsdorfer B, Giese T (2002) Quantitative expression of toll-like receptor 1–10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to CpG oligodeoxynucleotides. J Immunol 168:4531–4537
9. Hart OM, Athie-Morales V, O’Connor GM, Gardiner CM (2005) TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 175:1636–1642
10. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S (2004) Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science 303:1526–1529
11. Mansson A, Cardell LO (2009) Role of atopic status in Toll-like receptor (TLR)7- and TLR9-mediated activation of human eosinophils. J Leukoc Biol 85:719–727
12. Pedersen G, Andresen L, Matthiessen MW, Rask-Madsen J, Brynskov J (2005) Expression of Toll-like receptor 9 and response to bacterial CpG oligodeoxynucleotides in human intestinal epithelium. Clin Exp Immunol 141:298–306
13. Gribar SC, Anand RJ, Sodhi CP, Hackam DJ (2008) The role of epithelial Toll-like receptor signaling in the pathogenesis of intestinal inflammation. J Leukoc Biol 83:493–498
14. Olson JK, Miller S (2004) Microglia initiate central nervous system innate and adaptive immune response through multiple TLRs. J Immunol 173(6):3916–3924
15. Napolitani G, Rinaldi A, Bertoni F, Sallusto F, Antonio Lanzavecchia (2005) Selected Toll-like receptor agonist combinations synergistically trigger a T helper type 1-polarizing program in dendritic cells. Nat Immunol 6:769–776
16. Nagai Y, Garrett KP, Ohta S, Bahrun U, Kouro T, Akira S, Takatsu K, Kincade PW (2006) Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 24(6):801–812
17. Boiko Julie R, Borghesi Lisa (2012) Hematopoiesis sculpted by pathogens: Toll-like receptors and inflammatory mediators directly activate stem cells. Cytokine 57:1–8
18. Kawai T, Akira S (2007) TLR signaling. Semin Immunol 19(1):24–32
19. Latz E, Schoenemeyer A, Visintin A (2004) TLR9 signals after translocating from the ER to CpG DNA in the lysosome. Nat Immunol 5(2):190–198
20. Ito T, Amakawa R, Kaisho T (2002) Interferon-α and interleukin-12 are induced differentially by Toll like receptor 7 ligands in human blood dendritic cell subsets. J Exp Med 195(11):1507–1512
21. Rubnitz JE, Gibson B, Smith FO (2010) Acute myeloid leukemia. Hematol Oncol Clin N Am 24(1):35–63
22. Baldus CD, Bullinger L (2008) Gene expression with prognostic implications in cytogenetically normal acute myeloid leukemia. Semin Oncol 35(4):356–364
23. Smits EL, Cools N, Lion E, Van Camp K, Ponsaerts P, Berneman ZN, Van Tendeloo VF (2010) The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. Cancer Immunol Immunother 59(1):35–46
24. Schmitt A, Li L, Giannopoulos K, Greiner J, Reinhardt P, Wiesneth M, Schmitt M (2008) Quantitative expression of Toll-like receptor-2, -4, and -9 in dendritic cells generated from blasts of patients with acute myeloid leukemia. Transfusion 48(5):861–870
25. Robinson SP, English N, Jaju R, Kearney L, Knight SC, Reid CDL (1998) The in vitro generation of dendritic cells from blast cells in acute leukemia. Brit J Hematol 103:763–771
26. Charbonnier A, Gaugler B, Sainty D, Lafage-Pochitaloff M, Olive D (1999) Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias. Eur J Immunol 29:2567–2578
27. Cignetti A, Bryant E, Allione B, Vitale A, Foa R, Cheever MA (1999) CD34+ acute myeloid and lymphoid leukemic blasts can be induced to differentiate into dendritic cells. Blood 94:2048–2055
28. Choudhury BA, Liang JC, Thomas EK (1999) Dendritic cells derived in vitro from acute myelogenous leukemia cells stimulate autologous, antileukemic T-cell responses. Blood 93:780–786
29. Woiciechowsky A, Regn S, Kolb HJ, Roskrow M (2001) Leukemic dendritic cells generated in the presence of FLT3 ligand have the capacity to stimulate an autologous leukemia-specific cytotoxic T cell response from patients with acute myeloid leukemia. Leukemia 15:246–255
30. Gruijl TD, Eertwegh AJM, Pinedo HM, Scheper RJ (2008) Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccines. Cancer Immunol Immunother 57:1569–1577
31. Cheuk ATC, Ba Guinn (2008) Immunotherapy of acute myeloid leukaemia: development of a whole cell vaccine. Front Biosci 13:2022–2029
32. Zhong RK, Lane TA, Ball ED (2008) Generation of T cell lines to autologous acute myeloid leukemia (AML) cells by competitive limiting dilution culture of AML mononuclear cells (MNC). Exp Hematol 36(4):486–494
33. Jedema I, van der Werff NM, Barge RM, Willemze R, Falkenburg JH (2004) New CFSE-based assay to determine susceptibility to lysis by cytotoxic T cells of leukemic precursor cells within a heterogeneous target cell population. Blood 103(7):2677–2682
34. R Core Team (2014) R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/
35. McIlroy D, Gregoire M (2003) Optimizing dendritic cell-based anticancer immunotherapy: maturation state does have clinical impact. Cancer Immunol Immunother 52(10):583–591
36. Thurner B, Roder C, Dieckmann D, Heuer M, Kruse M, Glaser A (1999) Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods 223(1):1–15
37. Jonuleit H, Giesecke-Tuettenberg A, Tuting T, Thurner-Schuler B, Stuge TB, Paragnik L, Kandemir A, Lee PP, Schuler G, Knop J, Enk AH (2001) A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int J Cancer 93:243–251
38. Cheever MA (2008) Twelve immunotherapy drugs that could cure cancers. Immunol Rev 222:357–368
39. Schürch C, Riether C, Amrein M, Ochsenbein A (2013) Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ. J Exp Med 210(3):605–621